



Clinical trial results:

An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to a 2-4-11 months vaccination schedule.

Summary

EudraCT number	2005-003437-41
Trial protocol	SE DK SK
Global end of trial date	25 January 2007

Results information

Result version number	v2
This version publication date	20 March 2016
First version publication date	14 March 2015
Version creation reason	<ul style="list-style-type: none">• Correction of full data setCorrection of errors detected in immunogenicity data

Trial information

Trial identification

Sponsor protocol code	105539
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00307034
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 June 2007
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	25 January 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the post-dose 2 immune response elicited by GSK Biologicals' 10-valent pneumococcal conjugate vaccine administered according to a 2-4-11 months vaccination schedule with co-administration of DTPa combined vaccine.

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 January 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Norway: 85
Country: Number of subjects enrolled	Slovakia: 75
Country: Number of subjects enrolled	Sweden: 61
Country: Number of subjects enrolled	Denmark: 130
Worldwide total number of subjects	351
EEA total number of subjects	351

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	351
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details: -

Pre-assignment period milestones

Number of subjects started	351
Number of subjects completed	351

Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	2-dose priming group

Arm description:

Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 2-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2 and 4 months of age, followed by a booster dose of the same vaccine at 11 months of age, each dose being co-administered with one dose of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.

Arm type	Experimental
Investigational medicinal product name	10-valent Streptococcus pneumoniae conjugate vaccine
Investigational medicinal product code	
Other name	10Pn-PD-DiT
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 primary doses of 10Pn-PD-DiT vaccine at 2 and 4 months of age, with first vaccine dose at 8-16 weeks of age. A 3rd dose of 10Pn-PD-DiT (i.e. booster dose) was administered at 11 months of age.

Investigational medicinal product name	Infanrix hexa™
Investigational medicinal product code	
Other name	DTPa-HBV-IPV/Hib, DTPa combined vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of DTPa combined vaccine administered at 2 and 4 months of age, with first vaccine dose at 8-16 weeks of age. A 3rd dose of DTPa combined vaccine at 11 months of age.

Investigational medicinal product name	Infanrix™ IPV Hib
Investigational medicinal product code	
Other name	DTPa-IPV/Hib, DTPa combined vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of DTPa combined vaccine administered at 2 and 4 months of age, with first vaccine dose at 8-

16 weeks of age. A 3rd dose of DTPa combined vaccine at 11 months of age.

Arm title	3-dose priming group
------------------	----------------------

Arm description:

Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2, 3 and 4 months of age, co-administered with 2 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations at 2 and 4 months of age, followed by a booster dose of the 10Pn-PD-DiT vaccine at 11 months of age, co-administered with one dose of the DTPa combined vaccine. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.

Arm type	Comparator
Investigational medicinal product name	10-valent Streptococcus pneumoniae conjugate vaccine
Investigational medicinal product code	
Other name	10Pn-PD-DiT
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 primary doses of 10Pn-PD-DiT vaccine and 3 doses of DTPa combined vaccine co-administered at 2, 3 and 4 months of age, with first vaccine dose at 8-16 weeks of age. A 4rd dose of 10Pn-PD-DiT (i.e. booster dose) was co-administered with a 3rd dose of DTPa combined vaccine at 11 months of age.

Investigational medicinal product name	Infanrix hexa™
Investigational medicinal product code	
Other name	DTPa-HBV-IPV/Hib, DTPa combined vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of DTPa combined vaccine administered at 2 and 4 months of age, with first vaccine dose at 8-16 weeks of age. A 3rd dose of DTPa combined vaccine at 11 months of age.

Investigational medicinal product name	Infanrix™ IPV Hib
Investigational medicinal product code	
Other name	DTPa-IPV/Hib, DTPa combined vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of DTPa combined vaccine administered at 2 and 4 months of age, with first vaccine dose at 8-16 weeks of age. A 3rd dose of DTPa combined vaccine at 11 months of age.

Number of subjects in period 1	2-dose priming group	3-dose priming group
Started	175	176
Completed	173	169
Not completed	2	7
Consent withdrawn by subject	1	2
Adverse event, non-fatal	1	2
Lost to follow-up	-	3

Baseline characteristics

Reporting groups

Reporting group title	2-dose priming group
-----------------------	----------------------

Reporting group description:

Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 2-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2 and 4 months of age, followed by a booster dose of the same vaccine at 11 months of age, each dose being co-administered with one dose of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.

Reporting group title	3-dose priming group
-----------------------	----------------------

Reporting group description:

Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2, 3 and 4 months of age, co-administered with 2 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations at 2 and 4 months of age, followed by a booster dose of the 10Pn-PD-DiT vaccine at 11 months of age, co-administered with one dose of the DTPa combined vaccine. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.

Reporting group values	2-dose priming group	3-dose priming group	Total
Number of subjects	175	176	351
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: weeks			
arithmetic mean	12	12.1	
standard deviation	± 1.94	± 1.9	-
Gender categorical			
Units: Subjects			
Female	86	82	168
Male	89	94	183

End points

End points reporting groups

Reporting group title	2-dose priming group
Reporting group description: Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 2-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2 and 4 months of age, followed by a booster dose of the same vaccine at 11 months of age, each dose being co-administered with one dose of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.	
Reporting group title	3-dose priming group
Reporting group description: Healthy male or female subjects between, and including 8 to 16 weeks (56-120 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of 10Pn-PD-DiT, vaccine at 2, 3 and 4 months of age, co-administered with 2 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix™ IPV Hib (DTPa-IPV/Hib), according to national recommendations at 2 and 4 months of age, followed by a booster dose of the 10Pn-PD-DiT vaccine at 11 months of age, co-administered with one dose of the DTPa combined vaccine. 10Pn-PD-DiT vaccine was administered intramuscularly into the right anterolateral thigh and DTPa combined vaccine was administered intramuscularly into the left anterolateral thigh.	

Primary: Number of subjects with anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.20 µg/mL

End point title	Number of subjects with anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.20 µg/mL ^[1]
End point description: Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. This outcome concerns results for the Primary Phase of the study. The results presented for the Group 1 correspond to the primary outcome.	
End point type	Primary
End point timeframe: At Month 3, e.g. one month after the administration of the second dose (in a 2-4-11 months of age vaccination schedule) or one month after the administration of the third dose (in a 2-3-4-11 months of age vaccination schedule) with 10Pn-PD-DiT vaccine.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	153	153		
Units: Subjects				
Anti-1 (N= 153, 151)	149	149		
Anti-4 (N=153, 153)	150	152		
Anti-5 (N=152, 149)	146	149		
Anti-6B (N=149, 149)	83	94		

Anti-7F (N=153, 152)	148	151		
Anti-9V (N=152, 153)	142	152		
Anti-14 (N=152, 152)	146	152		
Anti-18C (N=152, 153)	146	152		
Anti-19F (N=152, 152)	141	146		
Anti-23F (N=153, 152)	106	118		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations $\geq 0.20 \mu\text{g/mL}$

End point title	Number of subjects with Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations $\geq 0.20 \mu\text{g/mL}$
-----------------	--

End point description:

Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter ($\mu\text{g/mL}$). The seropositivity cut-off of the assay was an antibody concentration $\geq 0.05 \mu\text{g/mL}$. This outcome concerns results for the Booster Phase of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of 10Pn-PD-DiT vaccine

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156	149		
Units: Subjects				
Anti-1 at Month 9 (N= 149, 147)	77	101		
Anti-1 at Month 10 (N=156, 147)	155	147		
Anti-4 at Month 9 (N= 152, 149)	120	137		
Anti-4 at Month 10 (N=155, 147)	155	147		
Anti-5 at Month 9 (N= 148, 149)	121	133		
Anti-5 at Month 10 (N=155, 147)	155	147		
Anti-6B at Month 9 (N= 154, 148)	101	111		
Anti-6B at Month 10 (N=156, 147)	138	142		
Anti-7F at Month 9 (N= 151, 149)	135	146		
Anti-7F at Month 10 (N=156, 147)	156	147		
Anti-9V at Month 9 (N= 153, 149)	133	142		
Anti-9V at Month 10 (N=156, 147)	155	147		
Anti-14 at Month 9 (N= 151, 149)	140	147		
Anti-14 at Month 10 (N=156, 147)	155	145		
Anti-18C at Month 9 (N= 154, 149)	133	144		
Anti-18C at Month 10 (N=156, 147)	156	146		

Anti-19F at Month 9 (N= 153, 149)	140	143		
Anti-19F at Month 10 (N=156, 147)	150	144		
Anti-23F at Month 9 (N= 151, 148)	108	116		
Anti-23F at Month 10 (N=154, 147)	148	141		

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

End point title	Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
-----------------	--

End point description:

Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. 1 month after second dose (in a 2-4-11 months of age schedule) or third dose (in a 2-3-4-11 months of age schedule), at Month 9 e.g. before booster dose and at Month 10, e.g. 1 month after booster dose of 10Pn-PD-DiT vaccine.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156	153		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1 at Month 3 (N= 153, 151)	1.03 (0.9 to 1.18)	1.23 (1.07 to 1.42)		
Anti-1 at Month 9 (N= 149, 147)	0.21 (0.19 to 0.24)	0.3 (0.26 to 0.34)		
Anti-1 at Month 10 (N=156, 147)	1.85 (1.59 to 2.15)	1.88 (1.62 to 2.17)		
Anti-4 at Month 3 (N= 153, 153)	1.37 (1.21 to 1.55)	1.71 (1.47 to 1.99)		
Anti-4 at Month 9 (N= 152, 149)	0.4 (0.35 to 0.46)	0.64 (0.56 to 0.73)		
Anti-4 at Month 10 (N=155, 147)	3.06 (2.68 to 3.49)	3.47 (3.03 to 3.98)		
Anti-5 at Month 3 (N= 152, 149)	1.32 (1.14 to 1.52)	1.85 (1.63 to 2.1)		
Anti-5 at Month 9 (N= 148, 149)	0.43 (0.37 to 0.5)	0.59 (0.51 to 0.68)		
Anti-5 at Month 10 (N=155, 147)	2.65 (2.31 to 3.03)	3.21 (2.81 to 3.67)		
Anti-6B at Month 3 (N= 149, 149)	0.19 (0.15 to 0.24)	0.31 (0.25 to 0.38)		

Anti-6B at Month 9 (N= 154, 148)	0.28 (0.23 to 0.35)	0.44 (0.36 to 0.54)		
Anti-6B at Month 10 (N=156, 147)	1.12 (0.88 to 1.41)	1.85 (1.54 to 2.22)		
Anti-7F at Month 3 (N= 153, 152)	1.28 (1.13 to 1.46)	2.14 (1.9 to 2.4)		
Anti-7F at Month 9 (N= 151, 149)	0.55 (0.49 to 0.63)	0.92 (0.81 to 1.05)		
Anti-7F at Month 10 (N=156, 147)	2.81 (2.51 to 3.15)	3.88 (3.45 to 4.37)		
Anti-9V at Month 3 (N= 152, 153)	0.92 (0.81 to 1.05)	1.47 (1.29 to 1.68)		
Anti-9V at Month 9 (N= 153, 149)	0.52 (0.46 to 0.6)	0.87 (0.77 to 0.99)		
Anti-9V at Month 10 (N=156, 147)	2.95 (2.59 to 3.37)	3.97 (3.49 to 4.5)		
Anti-14 at Month 3 (N= 152, 152)	1.72 (1.45 to 2.05)	2.57 (2.22 to 2.97)		
Anti-14 at Month 9 (N= 151, 149)	0.77 (0.64 to 0.93)	1.53 (1.27 to 1.85)		
Anti-14 at Month 10 (N=156, 147)	4.19 (3.62 to 4.85)	5.47 (4.68 to 6.4)		
Anti-18C at Month 3 (N= 152, 153)	1.26 (1.06 to 1.51)	3.42 (2.87 to 4.07)		
Anti-18C at Month 9 (N= 154, 149)	0.59 (0.5 to 0.69)	1.14 (0.96 to 1.35)		
Anti-18C at Month 10 (N=156, 147)	6.24 (5.43 to 7.18)	7.2 (6.08 to 8.52)		
Anti-19F at Month 3 (N= 152, 152)	2.43 (1.97 to 2.98)	4.43 (3.6 to 5.45)		
Anti-19F at Month 9 (N= 153, 149)	1.04 (0.87 to 1.25)	1.7 (1.41 to 2.04)		
Anti-19F at Month 10 (N=156, 147)	5.58 (4.65 to 6.69)	6.95 (5.92 to 8.17)		
Anti-23F at Month 3 (N= 153, 152)	0.38 (0.3 to 0.47)	0.52 (0.42 to 0.63)		
Anti-23F at Month 9 (N= 151, 148)	0.32 (0.26 to 0.4)	0.44 (0.36 to 0.54)		
Anti-23F at Month 10 (N=154, 147)	2.41 (1.98 to 2.94)	2.78 (2.31 to 3.35)		

Statistical analyses

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

End point title	Titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
-----------------	---

End point description:

Seropositivity status defined as Opsonophagocytic activity against pneumococcal serotypes ≥ 8 . This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. 1 month after second dose (in a 2-4-11 months of age schedule) or third dose (in a 2-3-4-11 months of age schedule), at Month 9 e.g. before booster dose and at Month 10, e.g. 1 month

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	135		
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-1 at Month 3 (N= 130, 132)	21.9 (16.4 to 29.1)	26.5 (19.8 to 35.4)		
Opsono-1 at Month 9 (N= 136, 134)	5.1 (4.5 to 5.8)	6.7 (5.4 to 8.3)		
Opsono-1 at Month 10 (N=131, 126)	109.9 (76.1 to 158.7)	100.6 (68.9 to 146.9)		
Opsono-4 at Month 3 (N= 134, 132)	462.6 (410.4 to 521.4)	758.9 (647.8 to 888.9)		
Opsono-4 at Month 9 (N= 104, 114)	13.8 (9.7 to 19.6)	18.6 (12.7 to 27.2)		
Opsono-4 at Month 10 (N=125, 101)	634.6 (496.3 to 811.3)	1204 (990.7 to 1463.2)		
Opsono-5 at Month 3 (N= 132, 130)	48.3 (37.7 to 61.8)	68.4 (54 to 86.5)		
Opsono-5 at Month 9 (N= 133, 135)	9.9 (8.1 to 12)	10.7 (8.6 to 13.4)		
Opsono-5 at Month 10 (N=133, 121)	102.1 (75.8 to 137.6)	157.2 (123.1 to 200.7)		
Opsono-6B at Month 3 (N= 125, 126)	157.8 (104.7 to 237.8)	379.6 (272.4 to 529.1)		
Opsono-6B at Month 9 (N= 121, 124)	56.1 (34.9 to 90.4)	62.9 (40.2 to 98.5)		
Opsono-6B at Month 10 (N=132, 103)	220.3 (146.9 to 330.3)	468.5 (311.6 to 704.3)		
Opsono-7F at Month 3 (N= 127, 131)	844.8 (591.4 to 1206.7)	2176.5 (1759.2 to 2692.7)		
Opsono-7F at Month 9 (N= 113, 126)	148.5 (89.5 to 246.4)	380.6 (253 to 572.6)		
Opsono-7F at Month 10 (N=128, 109)	1843.4 (1494.2 to 2274.1)	3290.6 (2709.1 to 3996.8)		
Opsono-9V at Month 3 (N= 134, 132)	875.1 (732 to 1046.1)	1343.4 (1130.8 to 1596)		
Opsono-9V at Month 9 (N= 120, 134)	266.8 (205.1 to 347.1)	322.2 (256.4 to 405.1)		
Opsono-9V at Month 10 (N=129, 109)	1068.1 (874.7 to 1304.2)	1706.9 (1438.5 to 2025.3)		
Opsono-14 at Month 3 (N= 132, 131)	692.6 (559.1 to 858)	1125.3 (946.2 to 1338.3)		
Opsono-14 at Month 9 (N= 102, 123)	52.1 (32.4 to 84)	157.3 (108.5 to 228.1)		
Opsono-14 at Month 10 (N=107, 101)	835.5 (672.1 to 1038.5)	1280.7 (1054.5 to 1555.5)		
Opsono-18C at Month 3 (N= 134, 131)	56.2 (42.9 to 73.7)	218.6 (176.1 to 271.4)		

Opsono-18C at Month 9 (N= 122, 126)	8.3 (6.5 to 10.7)	16.9 (12.5 to 22.8)		
Opsono-18C at Month 10 (N=136, 130)	330 (259.1 to 420.3)	490.8 (395.3 to 609.4)		
Opsono-19F at Month 3 (N= 131, 128)	101 (74.9 to 136)	356.7 (263.2 to 483.4)		
Opsono-19F at Month 9 (N= 130, 134)	16.5 (12.9 to 21.1)	31.6 (24.5 to 40.8)		
Opsono-19F at Month 10 (N=131, 129)	251.3 (193.4 to 326.6)	734.7 (568.3 to 949.8)		
Opsono-23F at Month 3 (N= 131, 129)	489.7 (342.6 to 700)	1233.7 (991.7 to 1534.7)		
Opsono-23F at Month 9 (N= 112, 133)	190.7 (115.2 to 315.6)	150.7 (95.9 to 236.8)		
Opsono-23F at Month 10 (N=134, 121)	1047.3 (748.1 to 1466.3)	1528.9 (1171.2 to 1996)		

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (ANTI-PD)

End point title	Concentrations of antibodies against protein D (ANTI-PD)
-----------------	--

End point description:

ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status is defined as Anti-PD antibody concentrations ≥ 100 EL.U/mL. This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. 1 month after second dose (in a 2-4-11 months of age schedule) or third dose (in a 2-3-4-11 months of age schedule), at Month 9 e.g. before booster dose and at Month 10, e.g. 1 month after booster dose of 10Pn-PD-DiT vaccine.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	154	148		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD at Month 3 (N=149, 148)	861.8 (740.4 to 1003.1)	1223.3 (1066.5 to 1403.2)		
Anti-PD at Month 9 (N= 151, 148)	349.7 (294.2 to 415.7)	499.8 (425.3 to 587.2)		
Anti-PD at Month 10 (N= 154, 146)	1629.8 (1346.4 to 1972.8)	2113 (1808.9 to 2468.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against diphtheria (Anti-D) and tetanus (Anti-T).

End point title	Concentrations of antibodies against diphtheria (Anti-D) and tetanus (Anti-T).
-----------------	--

End point description:

Concentrations of antibodies are presented as geometric mean concentrations expressed as International units per milliliter (IU/mL). Seroprotection status defined as Anti-diphtheria and anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. one month after the administration of the second dose, at Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of DTPa combined vaccine

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156	151		
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-D at Month 3 (N=154, 151)	1.791 (1.503 to 2.133)	3.123 (2.621 to 3.723)		
Anti-D at Month 9 (N= 154, 148)	0.326 (0.275 to 0.386)	0.725 (0.622 to 0.846)		
Anti-D at Month 10 (N= 156, 148)	5.423 (4.815 to 6.108)	8.262 (7.339 to 9.301)		
Anti-T at Month 3 (N=154, 151)	2.504 (2.17 to 2.89)	4.602 (4.062 to 5.213)		
Anti-T at Month 9 (N= 153, 149)	0.565 (0.487 to 0.656)	1.191 (1.055 to 1.344)		
Anti-T at Month 10 (N= 156, 148)	7.678 (6.997 to 8.425)	9.597 (8.749 to 10.526)		

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP)

End point title	Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP)
End point description: Concentrations of antibodies are presented as geometric mean concentrations expressed as micrograms per milliliter (µg/mL). Seroprotection status defined as anti-PRP antibody concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL. This outcome concerns results for the Primary and Booster Phases of the study.	
End point type	Secondary
End point timeframe: At Month 3, e.g. one month after the administration of the second dose, at Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of DTPa combined vaccine	

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	155	148		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-PRP at Month 3 (N=146, 147)	1.179 (0.893 to 1.556)	2.186 (1.648 to 2.9)		
Anti-PRP at Month 9 (N= 150, 148)	0.431 (0.349 to 0.532)	0.777 (0.613 to 0.984)		
Anti-PRP at Month 10 (N= 155, 147)	16.943 (13.485 to 21.287)	21.654 (17.263 to 27.161)		

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against pertussis toxoid (Anti-PT), against filamentous haemagglutinin (Anti-FHA) and pertactin (Anti-PRN)

End point title	Concentrations of antibodies against pertussis toxoid (Anti-PT), against filamentous haemagglutinin (Anti-FHA) and pertactin (Anti-PRN)
End point description: Concentrations of antibodies are presented as geometric mean concentrations expressed as enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status defined as anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL. This outcome concerns results for the Primary and Booster Phases of the study.	
End point type	Secondary
End point timeframe: At Month 3, e.g. one month after the administration of the second dose, at Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of DTPa combined vaccine	

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	150	147		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PT at Month 3 (N=145, 144)	36.1 (32.9 to 39.6)	33.8 (30.2 to 37.9)		
Anti-PT at Month 9 (N= 144, 145)	9.8 (8.7 to 11.1)	10.2 (8.9 to 11.7)		
Anti-PT at Month 10 (N= 149, 145)	78.2 (70.5 to 86.8)	65.5 (58.7 to 73.1)		
Anti-FHA at Month 3 (N=145, 144)	166.7 (150.1 to 185.2)	142.2 (125.6 to 161.1)		
Anti-FHA at Month 9 (N= 144, 145)	46.6 (41.3 to 52.6)	46.9 (41.1 to 53.6)		
Anti-FHA at Month 10 (N= 149, 144)	360.3 (323.7 to 401)	276.6 (249.4 to 306.7)		
Anti-PRN at Month 3 (N=145, 144)	83.9 (69.6 to 101.1)	89 (74.1 to 106.8)		
Anti-PRN at Month 9 (N= 144, 145)	13.7 (11.2 to 16.6)	18 (14.8 to 21.8)		
Anti-PRN at Month 10 (N= 150, 147)	275.5 (235.9 to 321.7)	209.3 (181.8 to 241)		

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against hepatitis B surface antigen (Anti-HBs) (subset of subjects who received DTPa-HBV-IPV/Hib as co-administered vaccine)

End point title	Concentrations of antibodies against hepatitis B surface antigen (Anti-HBs) (subset of subjects who received DTPa-HBV-IPV/Hib as co-administered vaccine)
-----------------	---

End point description:

Concentrations of antibodies are presented as geometric mean concentrations expressed as milli International units per milliliter (IU/mL). Seroprotection status defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL.. This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. one month after the administration of the second dose, at Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of DTPa combined vaccine

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	46		
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs at Month 3 (N=37, 38)	293.7 (195.9 to 440.5)	478.6 (294.8 to 776.9)		
Anti-HBs at Month 9 (N= 40, 46)	84.3 (55.4 to 128.2)	156.6 (106.4 to 230.4)		
Anti-HBs at Month 10 (N= 27, 28)	1892.3 (1012.2 to 3537.6)	2922.4 (2010.4 to 4248.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Titers of antibodies against polio type 1, 2 and 3 (Anti-polio 1, 2 and 3) (subset of subjects who received DTPa-HBV-IPV/Hib as co-administered vaccine)

End point title	Titers of antibodies against polio type 1, 2 and 3 (Anti-polio 1, 2 and 3) (subset of subjects who received DTPa-HBV-IPV/Hib as co-administered vaccine)
-----------------	--

End point description:

Titers of antibodies are presented as geometric mean titers. Seroprotection status is defined as anti-Polio types 1, 2 and 3 antibody titers ≥ 8 . This outcome concerns results for the Primary and Booster Phases of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 3, e.g. one month after the administration of the second dose, at Month 9, e.g. before the booster dose and at Month 10, e.g. one month after the booster dose of DTPa combined vaccine

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	59		
Units: Titer				
geometric mean (confidence interval 95%)				
Anti-Polio 1 at Month 3 (N=47, 57)	88.5 (56.3 to 139.1)	99.1 (63.4 to 154.8)		
Anti-Polio 1 at Month 9 (N=45,39)	24.6 (15.6 to 38.8)	14.4 (8.9 to 23.1)		
Anti-Polio 1 at Month 10 (N=20,15)	1006.4 (541.8 to 1869.4)	645 (399.4 to 1041.7)		
Anti-Polio 2 at Month 3 (N=47,59)	57.7 (36.8 to 90.6)	40.5 (25 to 65.6)		
Anti-Polio 2 at Month 9 (N=44,40)	14.9 (10.7 to 20.9)	10.9 (7.2 to 16.4)		
Anti-Polio 2 at Month 10 (N=17,14)	522.4 (235.7 to 1157.7)	512.2 (186.4 to 1407.7)		

Anti-Polio 3 at Month 3 (N=50,57)	165.6 (109.3 to 250.8)	161 (98.7 to 262.8)		
Anti-Polio 3 at Month 9 (N=44,38)	15.1 (9.8 to 23.2)	14.7 (9 to 24.1)		
Anti-Polio 3 at Month 10 (N=5,11)	1910.8 (257.4 to 14185.3)	961.4 (388.3 to 2380.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with booster vaccine response to Anti-PT, Anti-FHA and Anti-PRN antibody

End point title	Number of subjects with booster vaccine response to Anti-PT, Anti-FHA and Anti-PRN antibody
-----------------	---

End point description:

Booster vaccine response to PT, FHA and PRN, defined as the appearance of antibodies in subjects who were seronegative (Pre-booster status S-) (i.e., with antibody concentrations < 5 EL.U/mL) just before booster dose, and at least two-fold increase of pre-vaccination antibody concentrations in those who were seropositive (Pre-booster status S+) (i.e., with antibody concentrations ≥ 5 EL.U/mL) just before booster dose

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 10, e.g. one month after the administration of the booster dose

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	137	142		
Units: Subjects				
Anti-PT-Pre-booster status S-(N=20,23)	20	23		
Anti-PT-Pre-booster status S+(N=117,117)	115	114		
Anti-PT-Pre-booster status Total(N=137,140)	135	137		
Anti-FHA-Pre-booster status S-(N=0,1)	0	1		
Anti-FHA-Pre-booster status S+(N=137,138)	132	129		
Anti-FHA-Pre-booster status Total(N=137,139)	132	130		
Anti-PRN-Pre-booster status S-(N=35,21)	35	21		
Anti-PRN-Pre-booster status S+(N=102,121)	101	119		
Anti-PRN-Pre-booster status Total(N=137,142)	136	140		

Statistical analyses

Secondary: Number of subjects with any and Grade 3 solicited local symptoms

End point title	Number of subjects with any and Grade 3 solicited local symptoms
-----------------	--

End point description:

Assessed local symptoms were pain, redness and swelling. Any = Occurrence of the specified solicited local symptom, regardless of intensity. Grade 3 Pain = Crying when limb was moved/spontaneously painful. Grade 3 Redness/Swelling = Redness/swelling at injection site larger than (>) 30 millimeters (mm).

Across doses= across the 2 doses of the 10Pn-PD-DiT vaccine in the 2-dose priming group and across the 3 doses of the 10Pn-PD-DiT vaccine in the 3-dose priming group.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 4-day (Day 0-3) period following the primary vaccination (across doses) and during the 4-day (Day 0-3) period following the booster vaccination (post Bst) with the 10PN-PD-DT vaccine.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	176		
Units: Subjects				
Any Pain, across doses (N=175;176)	92	110		
Grade 3 Pain, across doses (N=175;176)	14	12		
Any Redness, across doses (N=175;176)	137	135		
Grade 3 Redness, across doses (N=175;176)	4	6		
Any Swelling, across doses (N=175;176)	111	105		
Grade 3 Swelling, across doses (N=175;176)	20	16		
Any Pain, post Bst (N=174,169)	103	93		
Grade 3 Pain, post Bst (N=174,169)	7	5		
Any Redness, post Bst (N=174,169)	118	115		
Grade 3 Redness, post Bst (N=174,169)	20	20		
Any Swelling, post Bst (N=174,169)	97	99		
Grade 3 Swelling, post Bst (N=174,169)	19	15		

Statistical analyses

No statistical analyses for this end point

Secondary: Number/percentage of subjects with solicited general symptoms

End point title	Number/percentage of subjects with solicited general symptoms
-----------------	---

End point description:

Assessed solicited general symptoms were Drowsiness, Irritability/Fussiness (Irr./Fuss.), Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than [\geq] 38.0 degrees Celsius [$^{\circ}$ C]),. Any =

Occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Irr./Fuss. = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (>) 40.0°C. Across doses= across the 2 doses of the 10Pn-PD-DiT vaccine in the 2-dose priming group and across the 3 doses of the 10Pn-PD-DiT vaccine in the 3-dose priming group.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 4-day (Day 0-3) period following the primary vaccination (across doses) and during the 4-day (Day 0-3) period following the booster vaccination (post Bst) with the 10PN-PD-DT vaccine.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	176		
Units: Subjects				
Any Drowsiness, across doses (N=175;176)	130	130		
Grade 3 Drowsiness, across doses (N=175,176)	9	4		
Related Drowsiness, across doses (N=175,176)	123	124		
Any Fever, across doses (N=175,176)	108	116		
Grade 3 Fever, across doses (N=175,176)	0	0		
Related Fever, across doses (N=175,176)	106	108		
Any Irr./Fuss., across doses (N=175,176)	149	158		
Grade 3 Irr./Fuss., across doses (N=175,176)	18	28		
Related Irr./Fuss., across doses (N=175,176)	142	147		
Any Loss Appet., across doses (N=175,176)	81	88		
Grade 3 Loss Appet., across doses (N=175,176)	5	1		
Related Loss Appet., across doses (N=175,176)	75	81		
Any Drowsiness, post Bst (N=174,169)	97	79		
Grade 3 Drowsiness, post Bst (N=174,169)	6	2		
Related Drowsiness, post Bst (N=174,169)	83	71		
Any Fever, post Bst (N=174,169)	96	78		
Grade 3 Fever, post Bst (N=174,169)	1	0		
Related Fever, post Bst (N=174,169)	84	67		
Any Irr./Fuss., post Bst (N=174,169)	113	104		
Grade 3 Irr./Fuss., post Bst (N=174,169)	6	2		
Related Irr./Fuss., post Bst (N=174,169)	99	89		
Any Loss Appet., post Bst (N=174,169)	61	56		
Grade 3 Loss Appet., post Bst (N=174,169)	3	0		

Related Loss Appet., post Bst (N=174,169)	53	43		
--	----	----	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number (%) of subjects with unsolicited adverse events

End point title	Number (%) of subjects with unsolicited adverse events
-----------------	--

End point description:

An unsolicited AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For the marketed products administered in the study, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse of the product. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within the 31-day (Days 0-30) period post primary vaccination, across doses

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	176		
Units: Subjects				
Any AE	78	114		

Statistical analyses

No statistical analyses for this end point

Secondary: Number (%) of subjects with unsolicited adverse events

End point title	Number (%) of subjects with unsolicited adverse events
-----------------	--

End point description:

An unsolicited AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For the marketed products administered in the study, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse of the product. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within the 31-day (Days 0-30) period post booster vaccination.

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	174	171		
Units: Subjects				
Any AE	63	72		

Statistical analyses

No statistical analyses for this end point

Secondary: Number (%) of subjects with serious adverse events

End point title	Number (%) of subjects with serious adverse events
End point description: A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE, regardless of relationship to vaccination.	
End point type	Secondary
End point timeframe: During the primary vaccination period	

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	176		
Units: Subjects				
Any SAE	5	7		

Statistical analyses

No statistical analyses for this end point

Secondary: Number (%) of subjects with serious adverse events

End point title	Number (%) of subjects with serious adverse events
End point description: A SAE was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation, as per the medical or scientific judgement of the physician. Any = Occurrence of a SAE,	

regardless of relationship to vaccination

End point type	Secondary
End point timeframe:	
During the booster vaccination period.	

End point values	2-dose priming group	3-dose priming group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	174	171		
Units: Subjects				
Any SAE	2	1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: during the 4 days post-primary vaccination (across doses) and post-booster dose.
Unsolicited AEs: during 31 days post-primary vaccination (across doses) and post-booster dose. SAEs: during both primary and booster vaccination periods

Adverse event reporting additional description:

Analysis of AEs and SAEs was done on subjects with at least 1 primary vaccination dose. Analysis of solicited symptoms was done on subjects with at least 1 primary dose and with results available. Occurrences (all and "related to the treatment") were not calculated during the analysis and are filled in with "subjects affected" similar information.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	10.0

Reporting groups

Reporting group title	2-dose priming Group
-----------------------	----------------------

Reporting group description:

Group 1

Reporting group title	3-dose priming Group
-----------------------	----------------------

Reporting group description:

Group 2

Serious adverse events	2-dose priming Group	3-dose priming Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 175 (2.86%)	7 / 176 (3.98%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Nervous system disorders			
Febrile convulsion	Additional description: Reported during Booster phase		
subjects affected / exposed ^[1]	1 / 174 (0.57%)	0 / 171 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Dyspepsia	Additional description: Reported during Primary phase		
subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma	Additional description: Reported during Primary phase		

subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis allergic	Additional description: Reported during Primary phase		
subjects affected / exposed	1 / 175 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Respiratory syncytial virus infection	Additional description: Reported during Primary phase		
subjects affected / exposed	1 / 175 (0.57%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia	Additional description: Reported during Primary phase		
subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis	Additional description: Reported during Primary phase		
subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral	Additional description: Reported during Primary phase		
subjects affected / exposed	1 / 175 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection	Additional description: Reported during Primary phase		
subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonellosis	Additional description: Reported during Primary phase		
subjects affected / exposed	1 / 175 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis	Additional description: Reported during Primary phase		

subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection-Primary phase			
	Additional description: Reported during Primary phase		
subjects affected / exposed	0 / 175 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
	Additional description: Reported during Primary phase		
subjects affected / exposed	1 / 175 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
	Additional description: Reported during Booster phase		
subjects affected / exposed ^[2]	0 / 174 (0.00%)	1 / 171 (0.58%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
	Additional description: Reported during Booster phase		
subjects affected / exposed ^[3]	1 / 174 (0.57%)	0 / 171 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection-Booster phase			
	Additional description: Reported during Booster phase		
subjects affected / exposed ^[4]	1 / 174 (0.57%)	0 / 171 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Analysis of serious adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Analysis of serious adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Analysis of serious adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Analysis of serious adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	2-dose priming Group	3-dose priming Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	149 / 175 (85.14%)	158 / 176 (89.77%)	
General disorders and administration site conditions			
Pain-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	92 / 175 (52.57%)	110 / 176 (62.50%)	
occurrences (all)	92	110	
Redness-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	137 / 175 (78.29%)	135 / 176 (76.70%)	
occurrences (all)	137	135	
Swelling-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	111 / 175 (63.43%)	105 / 176 (59.66%)	
occurrences (all)	111	105	
Pain-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[5]	103 / 174 (59.20%)	93 / 169 (55.03%)	
occurrences (all)	103	93	
Redness-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[6]	118 / 174 (67.82%)	115 / 169 (68.05%)	
occurrences (all)	118	115	
Swelling-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[7]	97 / 174 (55.75%)	99 / 169 (58.58%)	
occurrences (all)	97	99	
Drowsiness-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	130 / 175 (74.29%)	130 / 176 (73.86%)	
occurrences (all)	130	130	
Fever (rectally, ≥38°C)-primary phase			
alternative assessment type: Systematic			

subjects affected / exposed	108 / 175 (61.71%)	116 / 176 (65.91%)	
occurrences (all)	108	116	
Irritability-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	149 / 175 (85.14%)	158 / 176 (89.77%)	
occurrences (all)	149	158	
Loss of appetite-primary phase			
alternative assessment type: Systematic			
subjects affected / exposed	81 / 175 (46.29%)	88 / 176 (50.00%)	
occurrences (all)	81	88	
Drowsiness-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[8]	97 / 174 (55.75%)	79 / 169 (46.75%)	
occurrences (all)	97	79	
Fever (rectally, $\geq 38^{\circ}\text{C}$)-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[9]	96 / 174 (55.17%)	78 / 169 (46.15%)	
occurrences (all)	96	78	
Irritability-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[10]	113 / 174 (64.94%)	104 / 169 (61.54%)	
occurrences (all)	113	104	
Loss of appetite-booster phase			
alternative assessment type: Systematic			
subjects affected / exposed ^[11]	61 / 174 (35.06%)	56 / 169 (33.14%)	
occurrences (all)	61	56	
Pyrexia-primary phase			
subjects affected / exposed	12 / 175 (6.86%)	12 / 176 (6.82%)	
occurrences (all)	12	12	
Pyrexia-booster phase			
subjects affected / exposed ^[12]	8 / 174 (4.60%)	10 / 171 (5.85%)	
occurrences (all)	8	10	
Gastrointestinal disorders			

Diarrhoea subjects affected / exposed occurrences (all)	11 / 175 (6.29%) 11	8 / 176 (4.55%) 8	
Vomiting subjects affected / exposed occurrences (all)	4 / 175 (2.29%) 4	10 / 176 (5.68%) 10	
Respiratory, thoracic and mediastinal disorders Cough-primary phase subjects affected / exposed occurrences (all)	9 / 175 (5.14%) 9	9 / 176 (5.11%) 9	
Cough-booster phase subjects affected / exposed ^[13] occurrences (all)	6 / 174 (3.45%) 6	11 / 171 (6.43%) 11	
Infections and infestations Nasopharyngitis-primary phase subjects affected / exposed occurrences (all)	26 / 175 (14.86%) 26	46 / 176 (26.14%) 46	
Nasopharyngitis-booster phase subjects affected / exposed ^[14] occurrences (all)	16 / 174 (9.20%) 16	20 / 171 (11.70%) 20	
Otitis media subjects affected / exposed ^[15] occurrences (all)	9 / 174 (5.17%) 9	7 / 171 (4.09%) 7	

Notes:

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

[15] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events during the booster phase was done on subjects with at least 1 primary dose and with results available during this phase.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported